Zura Bio Ltd (ZURA) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001855644

P/B 3.57

P/E -6.18

P/S 0.00

Market Cap 386.66 Mn

ROIC (Qtr) -61.98

Div Yield % 0.00

Rev 1y % (Qtr) 0.00

Total Debt (Qtr) 0.00

Debt/Equity (Qtr) 0.00

About

Zura Bio Ltd, a biotechnology company that operates under the stock symbol ZURA, is dedicated to the development of innovative therapies for various diseases, with a particular focus on autoimmune conditions such as lupus, myositis, and eosinophilic disorders. The company boasts an experienced leadership team, headed by Dr. Somit Sidhu, who serves as the Founder, Chief Executive Officer, and Director, bringing a robust background in the life sciences industry. In the realm of biotechnology, Zura Bio engages in the development and commercialization...

Zura Bio Ltd, a biotechnology company that operates under the stock symbol ZURA, is dedicated to the development of innovative therapies for various diseases, with a particular focus on autoimmune conditions such as lupus, myositis, and eosinophilic disorders. The company boasts an experienced leadership team, headed by Dr. Somit Sidhu, who serves as the Founder, Chief Executive Officer, and Director, bringing a robust background in the life sciences industry.

In the realm of biotechnology, Zura Bio engages in the development and commercialization of a diverse range of therapeutic candidates, spanning various stages of clinical trials. The company's operations extend across numerous countries and regions, specifically in the area of autoimmune disease treatment.

Zura Bio's revenue generation hinges on the development and commercialization of its primary products, which are focused on treating autoimmune diseases. Notably, the company has developed a number of therapeutic candidates that have demonstrated promising results in clinical trials. The commercial segment of the company, led by Robert Lisicki, is tasked with building a robust sales and marketing infrastructure to support the launch of these products.

The company's position within the biotechnology industry is solidified by a number of competitive advantages. These include a strong team of experienced executives, innovative therapeutic candidates, and a targeted focus on autoimmune diseases. With a competitive edge over other biotechnology companies that are also developing therapeutic candidates for autoimmune diseases, Zura Bio's roster of competitors includes Pfizer, Johnson & Johnson, and Roche.

Zura Bio's customers primarily consist of pharmaceutical companies and research institutions that are interested in licensing the company's therapeutic candidates. Additionally, the company's products are being developed for use in clinical trials and are being tested in collaboration with various research institutions.

In terms of brand names and trade names, Zura Bio's offerings include a range of therapeutic candidates that are in various stages of clinical trials. While specific product names are not provided in the document, the company's focus on autoimmune diseases is evident in its product development efforts.

Stock Price Chart

Analysis

Pros

Operating cash flow of (53.36M) provides exceptional 64.21x coverage of minority interest expenses (831000), showing strong core operations.
Cash reserves of 139.02M provide robust 5.45x coverage of current liabilities 25.49M, indicating strong short-term solvency.
Cash position of 139.02M represents healthy 1.19x of working capital 116.80M, demonstrating strong operational liquidity.
Robust R&D investment of 40.37M at 1.25x of SG&A 32.20M demonstrates strong commitment to innovation and future growth.
Strong R&D investment of 40.37M at 286.28x of capex 141000 shows balanced investment in innovation and infrastructure.

Cons

Investment activities of (141000) provide weak support for R&D spending of 40.37M, which is -0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
The company's operating cash flow of (53.36M) shows concerning coverage of stock compensation expenses of 12.57M, with a -4.24 ratio indicating potential earnings quality issues.
Free cash flow of (53.50M) provides weak coverage of capital expenditures of 141000, with a -379.45 ratio suggesting additional external financing needs for growth initiatives.
Operating earnings of (64.27M) show weak coverage of depreciation charges of 39000, with a -1647.92 ratio indicating high capital intensity and potential reinvestment needs.
Operating cash flow of (53.36M) is outpaced by equity issuance of 5.18M (-10.30 ratio), indicating concerning reliance on equity markets for funding operations.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,349.40 Bn	-1,464.17	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	437.43 Bn	6,381.20	87.97	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	116.09 Bn	31.59	9.90	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	78.10 Bn	17.06	5.48	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	55.87 Bn	1,282.42	17.40	3.21 Bn
6	ARGX	Argenx Se	52.85 Bn	35.08	27,559.65	-
7	BNTC	Benitec Biopharma Inc.	41.75 Bn	-998.33	0.00	0.00 Bn
8	INSM	INSMED Inc	37.80 Bn	-31.93	84.56	0.74 Bn

Industry Comparisons

Current Valuation

Metric	Value	Industry
EV to Assets	1.61	12.31
EV to Cash from Ops.	-4.35	23.25
EV to Debt	0.00	738.44
EV to EBIT	-3.61	-9.16
EV to EBITDA	-3.20	6.95
EV to Free Cash Flow [EV/FCF]	-4.34	21.90
EV to Market Cap	0.60	65.67
EV to Revenue	0.00	227.32
Price to Book Value [P/B]	3.57	22.34
Price to Earnings [P/E]	-6.18	-11.77

Dividend Metrics

Metric	Value	Industry
Dividend Coverage Ratio	35.75	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	0.00	841.00

Growth Metrics

Metric	Value	Industry
Capex Growth (1y) %	-370.00	-27.13
Cash and Equivalents Growth (1y) %	-26.14	734.65
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	-36.02	-46.93
EBITDA Growth (1y) %	-44.25	-1.68
EBIT Growth (1y) %	-36.02	-56.45
EBT Growth (1y) %	-36.02	-12.70
EPS Growth (1y) %	-103.12	-28.31
FCF Growth (1y) %	-150.77	-31.90
Gross Profit Growth (1y) %	0.00	226.84

Liquidity Ratios

Metric	Value	Industry
Asset Utilization Ratio	0.00	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	5.45	3.85
Current Ratio	5.58	7.27
Debt to Equity Ratio	0.00	0.40
Interest Cover Ratio	0.00	841.00
Times Interest Earned	0.00	841.00

Profitability

Metric	Value	Industry	Percentile
EBITDA Margin %	0.00	-18,234.31
EBIT Margin %	0.00	-18,580.80
EBT Margin %	0.00	-19,488.74
Gross Margin %	0.00	-7.59
Net Profit Margin %	0.00	-19,439.22

Zura Bio Ltd (NASDAQ: ZURA)